New hope for blood disorder: first human trial of experimental drug combo begins
NCT ID NCT06502145
First seen Apr 05, 2026 · Last updated Apr 16, 2026 · Updated 2 times
Summary
This early-stage study aims to find a safe and effective dose of a new oral drug, iadademstat, when given alongside a standard chemotherapy drug, azacitidine. It is for adults with higher-risk forms of myelodysplastic syndrome (MDS), a type of bone marrow cancer. The main goal is to see how well patients tolerate the combination so it can be tested in larger future trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.